US/UK/Canada

Share

Contacts

  • Per Persson

    CEO


    Pharmacolog AB, Ekeby bruk 2H, SE75263 Uppsala, Sweden
    +46 18 500 101
    +46 73 746 44 61
    http://pharmacolog.com

    • Links

    Pick a time period -
    Tags ( Active)

    ANNOUNCEMENT FROM THE EXTRAORDINARY GENERAL MEETING OF PHARMACOLOG I UPPSALA AB ON APRIL 16, 2024

    Extraordinary General Meeting in Pharmacolog i Uppsala AB, reg. no. 556723-6418, (the "Company"), took place today, Wednesday, April 16, 2024, at 11.00 am at Clarion Hotell Gillet in Uppsala.All decisions were made in accordance with the Board's previously published proposal and with the required majority. Decisions new articles of association for the company It was resolved to change § 1 Company name in the articles of association to: "The company's company name is Perpetua Medical AB (publ). The company is public." In the event that the company name, for any reason, is not approved

    NOTICE TO EXTRAORDINARY GENERAL MEETING IN PHARMACOLOG I UPPSALA AB (PUBL)

    The shareholders of Pharmacolog i Uppsala AB (publ), reg. no. 556723-6418 (the "Company"), are hereby invited to an extraordinary general meeting on Tuesday, April 16, 2024 at 11:00 a.m. in Clarion Hotel Gillet's premises at Dragarbrunnsgatan 23, Uppsala.Right to attend the meeting Shareholders who wish to attend the meeting must: · be registered in their own name (not nominee registered) in the share register kept by Euroclear Sweden AB on the record date for the meeting, i.e. Monday, April 8, 2024, · notify the Company of their participation so that the notification is received

    Pharmacolog provides update on new business direction and proposes name change

    The Board of Directors has decided to proceed with the previously communicated business change. Against this background, Pharmacolog will convene an extraordinary general meeting in the manner prescribed by the Swedish Companies Act. The Board proposes a name change to Perpetua Medical AB (publ) and a new business direction, which includes the acquisition of smaller yet profitable companies in the healthcare sector. The background to this is that progress has been made regarding the investigation of a new business direction.In February, Pharmacolog announced that the Board intended to

    Pharmacolog announces upcoming change in management

    The company has decided by mutual agreement that Lars Gusch will step down from his current position as CEO on April 30, 2024.Pharmacolog announces that the currently appointed CEO Lars Gusch will step down from his position on April 30, 2024. This resignation is by mutual agreement with the Board of Directors, which in the meantime is working on the recruitment of a successor CEO, who will be announced in due course. Lars Gusch, CEO comments: "I would like to thank the Board of Directors for the trust they have placed in me and the good cooperation. Pharmacolog has gone through

    Warrants of series TO3 were subscribed to approximately 90.4 percent and Pharmacolog receives approximately SEK 2.3 million

    NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW. Pharmacolog i Uppsala AB (publ) (”Pharmacolog” or the ”Company”) announces today the outcome of the exercise of warrants of series TO3, which  were issued in connection with the Compan’'s rights issue of units on Nasdaq

    Major shareholder in Pharmacolog exercises warrants of series TO3 for at least approximately SEK 0.54 million

    NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW. The major shareholder Nolsterby Invest AB, that is controlled by the board members Erik Hedlund and Anders Hedlund exercises, warrants of series TO3 in Pharmacolog i Uppsala AB (“Pharmacolog” or the “Company”). The

    The last day of trading with warrants of series TO3 in Pharmacolog is today, February 20, 2024

    NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW. Today, February 20, 2024, is the last day of trading with the warrants of series TO3 in Pharmacolog i Uppsala AB (“Pharmacolog” or the “Company”). The exercise period for the warrants of series TO3 continues until February

    Year-end bulletin Pharmacolog 2023

    Press release: Uppsala, February 16, 2024 Pharmacolog i Uppsala AB (publ) year-end bulletin for the period January - December 2023 is now available on the company's website  and is attached as a pdf.Fourth quarter October 1 - December 31, 2023 · The Group's net sales for the fourth quarter amounted to KSEK 2 567 (1 785). · Operating profit for the quarter amounted to KSEK -4,159 (-6,763). · Net earnings per share for the quarter were SEK -0.06 (-0.36) before dilution and SEK -0.03 (-0.31) after dilution. The

    Pharmacolog investigates the possibilities for a new business direction

    Within the framework of the Board's established strategy, a significant milestone was recently communicated with the sale of Druglog to Raysearch Laboratories AB. Together with the cost-saving measures implemented by the Board, the financial risk is reduced to the extent that the company's position can pave the way for a new business direction. The Board intends to immediately investigate the conditions for a new business direction, which may include the acquisition of niche and profitable companies in the life science sector.The work of looking for and identifying potential acquisitions

    Pharmacolog terminates the partnership agreement with Codonics with immediate effect

    Pharmacolog terminates the existing partnership agreement with Codonics Inc. with immediate effect due to insufficient sales performance.In December 2020, Pharmacolog AB and Codonics Inc. entered into a partnership agreement for sales and marketing of WasteLog™ for the North American market, which over time has been expanded to include sales of DrugLog™ and several regions, such as China, the Middle East region, the GCC countries and Jordan, Mexico and Canada. This agreement established minimum sales targets for the DrugLog™ and WasteLog™ products, which were not closely met for either

    Pharmacolog divests part of its operations to RaySearch Laboratories AB

    Pharmacolog AB (Publ) announces today that the company will divest it's product line Druglog™ to RaySearch Laboratories AB through a so-called asset acquisition. The total value of the transaction amounts to SEK 8.5 million, of which the cash consideration is SEK 7 million , which will be paid at the time of the closing. Through this transaction, Druglog™ gains new and better conditions to develop commercially within RaySearch, for the benefit of cancer patients and healthcare providers worldwide.During the fourth quarter of 2024, the Board of Directors of Pharmacolog implemented a strategy

    The exercise period for warrants of series TO3 begins today

    NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW. Today, on February 9, 2024, the subscription period begins for the warrants of series TO3 in Pharmacolog i Uppsala AB (“Pharmacolog” or the “Company”). The subscription period runs until February 23, 2024.Summarized

    The subscription price for the exercise of warrants of series TO3 in Pharmacolog has been set at SEK 0.054 per share

    NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW. Pharmacolog in Uppsala AB (“Pharmacolog” or “the Company”) completed a rights issue of units on the Nasdaq First North Growth Market in July 2023. Each unit consisted of four (4) series B shares and four (4) warrants of

    Inova Healthcare selects WasteLog™

    Pharmacolog USA Inc. has received an order from Inova Healthcare for a WasteLog™ system to be placed at Inova Fair Oaks Hospital in Fairfax, VA.Inova is Northern Virginia’s leading nonprofit healthcare provider with more than 2 million patient visits each year through an integrated network of hospitals, primary and specialty care practices, emergency and urgent care centers, outpatient services, and destination institutes. Screening of controlled substance waste with WasteLog™ will be introduced at Inova Fair Oaks Hospital, a 174-bed acute care community hospital serving the rapidly growing

    Pharmacolog receives two DrugLog™ orders for installation in renowned hospitals in Europe.

    Pharmacolog has received orders for DrugLog™ systems for quality control of compounded medications in 2 additional hospitals in The Netherlands and Spain.One DrugLog™ order has been placed by Pharmacolog’s distributor Added Pharma on behalf of The Netherlands Cancer Institute, one of the world’s most comprehensive cancer centers, in Amsterdam. Additionally, B. Braun Medical Spain ordered a complete DrugLog™ system for installation at Hospital de A Coruña, one of the main hospitals in Galicia. The DrugLog™ systems will be used for quality control of prepared injectable drugs as a critical

    B. Braun orders two DrugLog™ for new installations in Spain

    B. Braun Medical Spain orders DrugLog™ systems for quality control of compounded medications in 2 additional hospitals.B. Braun Medical Spain orders two complete DrugLog™ systems based on the new hardware platform for installation at additional hospitals in Spain. The DrugLog™ systems will be used to verify the identity and concentration of prepared injectable drugs before they are administered to patients and will contribute to increased patient safety. Lars Gusch, CEO of Pharmacolog comments: "We are very pleased to deliver Pharmacolog's products to two more of B.Braun's customers in

    Pharmacolog publishes interim report January - September 2023

    Pharmacolog i Uppsala AB (publ) announces today that the interim report for the period January – September 2023 has been published.The annual report is attached as a PDF and is available on the company’s website:https://pharmacolog.com/investor-relations-2/financial-reports/ (Swedish only). Third quarter July 1 - September 30, 2023Consolidated net sales for the third quarter amounted to KSEK 1 361 (3 087).The operating result for the quarter amounted to KSEK -4,418 (-3,246).Net earnings per share for the quarter were SEK -0.07 (-0.20) before dilution and SEK -0.04 (-0.19) after

    ANNOUNCEMENT FROM THE EXTRAORDINARY GENERAL MEETING OF PHARMACOLOG I UPPSALA AB ON NOVEMBER 15, 2023

    Extraordinary General Meeting in Pharmacolog i Uppsala AB, reg. no. 556723-6418, (the "Company"), took place today, Wednesday, November 15, 2023, at 10.00 am at Clarion Hotell Gillet in Uppsala.  All decisions were made in accordance with the Board's previously published proposal and with the required majority.Decision on share capital reduction It was resolved to reduce the Company's share capital by a maximum of SEK 11,449,591.081, however not lower than SEK 662,138.90, for allocation to non-restricted equity. After the reduction has been carried out, in accordance with the proposal,

    Warrants of series TO2 were subscribed to approximately 1.65 percent and Pharmacolog i Uppsala AB receives approximately SEK 6.6 thousand

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, BELARUS, HONGKONG, JAPAN, CANADA, NEW ZEELAND, RUSSIA, SCHWEIZ, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Pharmacolog i Uppsala AB (publ) ("Pharmacolog" or "the Company") today announces the outcome of the exercise of warrants of series TO2, which were issued in

    NOTICE OF EXTRAORDINARY GENERAL MEETING IN PHARMACOLOG I UPPSALA AB (PUBL)

    The shareholders of Pharmacolog i Uppsala AB, reg. no. 556723-6418 (the "Company"), are hereby invited to an extraordinary general meeting on November 15, 2023 at 10.00 a.m. at Clarion Hotel Gillet, Dragarbrunnsgatan 23, Uppsala. Registration starts at 09.30 am.ELIGIBILITY AND NOTIFICATION Shareholders who wish to attend the general meeting shall · be entered in the share register maintained by Euroclear Sweden AB on November 7, 2023, · and no later than November 9, 2023, register with the Company for participation in the meeting. Notification of participation is made in

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe